# Actuate 1901: 9-ING-41 in Myelofibrosis

> **NCT04218071** · PHASE2 · COMPLETED · sponsor: **Actuate Therapeutics Inc.** · enrollment: 17 (actual)

## Conditions studied

- Myelofibrosis

## Interventions

- **DRUG:** Ruxolitinib
- **DRUG:** 9-ING-41

## Key facts

- **NCT ID:** NCT04218071
- **Lead sponsor:** Actuate Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-20
- **Primary completion:** 2022-10-13
- **Final completion:** 2024-01-18
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2024-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04218071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04218071, "Actuate 1901: 9-ING-41 in Myelofibrosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04218071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*